Кардиоваскулярные проблемы ревматологии

1. <div><p>Насонов ЕЛ. Современные направления иммунологических исследований при хронических воспалительных и аутоиммунных заболеваниях человека. Тер. архив, 2001. 8, 43-46</p><p>Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999, 340,115-126</p><p>von der Thusen J.H., Luiper J„ van Berkel T.J.C., Biessen B. A.L. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev., 2003, 55, 133166</p><p>Hansson G.K., Libby P., Schonbeck U., Yan Z.-Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circul. Res., 2002, 91, 281-291</p><p>Hansson G.K. Immune mechanisms in atherosclerosis. Arteriolscler. Thromb. Vase. Biol., 2001, 21, 1876-1890</p><p>Libby P. Vascular biology and atherosclerosis: overview and state of art. Am. J. Cardiol., 2003, 91 (suppl), 3A-6A</p><p>Blake G J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circulation Res., 2001, 89, 763-771.</p><p>Насонов ЕЛ, Иммунологические маркеры атеросклероза, Тер. архив, 2002, 5, 80-85</p><p>Bruce I.N., Gladman D.D., Urowitz М.В. Premature atherosclerosis in systemic lupus erythematosus. Rheum. Dis. Clin. North Amer., 2000, 26, 257-278</p><p>Goodson N. Coronary anery disease and rheumatoid arthritis. Curr. Opin. Rheumatol., 2002,14, 115-120</p><p>Manzi S., Wasco M.C.M., Manzi S. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann. Rheum. Dis., 2000, 58, 321-325</p><p>Solomon D.H, Karlson E.W., Rimm E.B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 2003, 107. 1303-1307</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in Early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthr. Rheum., 2002, 46, 2010-2019</p><p>Watson D.J., Rhodes T.„ Guess H.A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general practice research databse. J. Rheumatol., 2003, 50, 1196-1202</p><p>Turesson C., Jarenros A., Jacobson I. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann. Rheum. Dis., 2004, 63, 952-955</p><p>Boers М., Dijkmans B., Gabriel S. et al. Making an impact on mortality in rheumatoid arthritis. Targetting cardiovascular comorbidity. Arthr. Rheum., 2004, 50, 1734-1739</p><p>Fischer L.M., Schlienger R.G., Matter C. et al. Effects of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am. J. Cardiol., 2004. 93, 198-200</p><p>Manzi S. Systemic lupus erythematosus: a model for atherogenesis. Rheumatology, 2000, 39, 353-359</p><p>Thorburn C.M., Ward M.M. Hospitalization for coronary artery disease among patients with systemic lupus erythematosus. Arthr. Rheum., 2003, 48, 2519-2523</p><p>Bessant R,, Hingorani A., Patel L. et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology, 2004, 42, 924-928</p><p>Sattar N. McCrey D.W., Capell H., Mclnnes I.B. Explaining how "high-grade" systemic inflammation accelerated vascular risk in rheumatoid arthritis. Circulation, 2003, 108, 2957-2963</p><p>Pasceri V. Yeh E.T.H. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation, 1999,100. 2124-2126</p><p>Van Dortim S. McColl G., Wicks I.P. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis. Arthr. Rheum., 2002, 46, 862-875</p><p>Baxter J.D., Young W.F., Webb P. Cardiovascular endocrinology: introduction. Endocrin. Rev., 2003, 24, 253-260</p><p>Del Rincon I., Williams K., Stern M.P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr. Rheum., 2001, 44, 2737-2745</p><p>Esdale J.M., Abrahamowicz М., Grodzicky T. et al. Traditional Framingham risk factor fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheum., 2001, 44, 2331-2337</p><p>Rahman P., Urowitz M.B., Gladman D.D. et al. Contribution of traditional risk factor to coronary artery disease in patients with systemic lupus erythematosus, j. Rheumatol., 1999, 26 363-368</p><p>Roman M.J., Shanker В-A., Davis A. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl. J. Med., 2003, 349, 2399-2406</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet, 2002, 359, 1173-1177</p><p>De Groot E., Hovingh G.K., Wiegman A. et al. Measurement of arterial wall thickness as a surrogate marker for atherpsclerosis. Circulation. 2004, 109 (suppl. Ill), 1II-33-III-38</p><p>Manzi S., Selzer F., Sutton-Tyrrel K. et al. Prevalence and risk factor of carotid plaque in women with systemic lupus erythematosus. Arthr. Rheum., 1999, 42, 51-60.</p><p>Syenungson E., Jensen-Urstad K., Heimburger M. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation, 2001, 104, 1387-1893</p><p>Алекберова 3.C., Мач Э.С., Герасимова E.B. и др. Состояние периферических артерий у больных системной красной волчанкой Клин. Мед., 2004, 4, 46-49</p><p>van Doornum S., McColl G., Jenkins A. et al. Screening for atherosclerosis in patients with rheumatoid arthritis. Arthr. Rheum., 2003, 48, 72-80</p><p>Del Rincon I., Williams K., Stern M.P. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthr. Rheum., 2003, 48, 1833-1840</p><p>Park Y.-B., Ahn C.-W., Choi H.K. et al. Atherosclerosis in rheumatoid arthritis. Morphologic evidence obtained by carotid ultrasound. Arthr. Rheum., 2002, 46, 1714-1719</p><p>Kumeda Y., inaba М., Goto H. et al. Increased thickness of the arterial intima-medis detected by ultrasonography in patients with rheumatoid arthritis. Arthr. Rheum., 2002, 46, 1489-1497</p><p>Nagata-Sakurai М., Inaba М., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthr. Rheum., 2003, 48, 3061-3067</p><p>Romero-Diaz J., Barragan-Campos H., Romero C. et al. Atherosclerotic vascular disease in systemic lupus erythematosus (SLE). Yearly progression of the carotid intima- media thickness in the inception cohort. ACR/ARHP Annual Scientific Meeting, 2003, October 24-28, 896 (abst)</p><p>Ramsey-Goldman R., Manzi S. Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. Arthr. Rheum., 2001, 44, 2338-2341</p><p>Насонов ЕЛ. Остсопороч и заболевания сердечно-сосудистой системы. Кардиология, 2002, 3,80-82</p><p>Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction. A marker of atherosclerotic risk. Arteriol. Thromb. Vase. Biol., 2003, 23, 168-175</p><p>Wildansky M.E., Gokce N., Keaney J.F. et al. The clinical implications of endothelial dysfunction. J. Amer. Coll. Cardiol., 2003, 42. 1149-1160</p><p>Bergholm R., Leirisalo-Repo М., Vehkavaara S. et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arteriol. Thromb. Vase. Biol., 2002, 22, 1637-1641</p><p>Hurlimann D., Forster A., Noll G. et al. Antitumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation, 2002, 106, 2184-2187</p><p>Vaudo G., Marchesi S., Gerli R. et al. Endothelial dys- fubction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis., 2004, 63, 31-35</p><p>Gonzalez-Juanatey C., Testa A,, Garcia-Castelo A, et al. HLA-DRBI status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med,. 2003, 114, 647-652</p><p>Hansel S., Lasing G., Pistrosch F., Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis, 2003, 17, 177-180</p><p>Gonzalez-Juanatey C., Testa A., Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthr. Care &amp; Res., 2004, 51, 447-450</p><p>Hurlimann D., Forster A., Noll G. et al. Anti-tumor necrosis factor-a treatment improves endothelial function in patients with rheumatoid arthritis. Circulation, 2002, 106, 2184-2187</p><p>Ei-Magadmi М., Bodill H., Ahmad Y. et al. Systemic lupus erythematosus. An independent risk factor foe endothelial disfunction in women. Circulation, 2004, 310, 399-404</p><p>Fetnandez-Real J.M., Ricart W. Insulin rcsistence and chronic cardiovascular inflammatory syndrome. Endocrinol. Rev., 2003, 24, 278-301</p><p>Dessein P.H., Jofie B.I., Stanwix A. et al. The acute phase response does not fully predict the presence of insulin resistance and dislipidemia in inflammatory arthritis. J. Rheumatol., 2002, 24, 462-466</p><p>Dessein P.H., Stanwix A.E., Jofe B.l. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-den- sity lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthr. Res., 2002, 2, R5</p><p>Dessein P.H., Joffe B.I., Stamwix A.E. Inflammation, insulin resisience. and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J- Rheumatol., 2003, 30, 1403-1405</p><p>Dessein P.H., Joffe B.I., Stanwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis, J. Rheumatol. 2004, 31, 867-874</p><p>Posadas-Romero C., Torres-Tamayo М., Zamora- Gonzalez J. et al. High insulin levels and increased low- density lipoprotein oxidizability in prdiatric patients with systemic lupus erythematosus. Arthr. Rheum., 2004, 50, 160-165</p><p>El-Magadrni М., Turkie W., Yates A.P. et al. Hyperinsulinemia and insulin reasistence in women with systemic lupus erythematosus. Arthr. Rheum., 2002, 46 (suppl 9), S395 (abst)</p><p>Насонов Е.Л. Атеротромбоз при ревматических болезнях: анализ патогенеза. Тер. архив, 1998, 9, 92-95</p><p>Насонов ЕЛ. Антифосфолипилныit синдром. М., Лит- тера, 2004, 434</p><p>Martens Р.В., Goronzy J.J. Schaid D. et al. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthr. Rheum., 1997,1 40, 1106-1114</p><p>Liuzzo G. Kopecky S.L., Frye P.L. et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation, 1999. 100, 2135-2139</p><p>Gcrli R. Schillaci G„ Giordano A. et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rgcumatoid arthritis patients. Circulation, 2004, 109, 27442748</p><p>Бородин А.Г., Баранов А.А., Клюквина Н.Г. и др. Клинико-патогенетическое значение фактора некроза опухоли-альфа при системной красной волчанке. Тер. архив, 2002, 5, 32-35</p><p>Кричевскаи О.А., Клюквина Н.Г'., Александрова Е.Н. и др. Клиническое значение растворимых рецепторов фактора некроза опухоли-а у больных системной красной волчанкой. Клин, мед., 2004,10-16</p><p>Насонов Е.Л., Чичасова Н.В., Самсонов М.Ю. и др. Растворимые рецепторы фактора некроза опухоли при ревматоидном артрите. Клин, мед., 2001,8,33-36</p><p>Svenungsson Е., Fei G.-Z., Jensen-Urstad К. et al. TNF- alpha: a link between hyperglyceridemia and inflammation in SLE patients with cardiovascular disease. Lupus, 2003, 12, 451-461</p><p>Svenungsson E., Gunnarsson I., Fei G.-Z. et al. Elevated triglycerides anf low levels of high-density lipoprotein as marker of disease activity in association with uo-regulation of the tumor necrosis factor a/tumor necrosis factor system in systemic lupus erythematosus. Arthr. Rheum., 2003, 48, 2533-2540</p><p>Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primer for clinicians, 2002,Amgen, 351</p><p>Belton O., Fitzgerald D.J. Cycloxygenase isoform and atherosclerosis. Expert reviews in molecular medicine, http// www. expe rt re v ie ws. о rg/</p><p>Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН, 2003, 7, 6-10</p><p>Bombardier С., Lane L., Reicin A. et al, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl. J. Med., 2000, 343, 1520-1528</p><p>Crofford L.J., Oates J.C., McCune W.l. et al. Thrombosis in patients with connective tissue disease treated with specific cycloxygenase-2 inhibitors: a report of four cases. Arthr. Rheum., 2000, 3, 1891-1896</p><p>Mukherjee D., Nissen S.E., Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959</p><p>McAdam B.F., Catella-Lawson F., Mardini I.A. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2. PNAS, 1999, 96, 272-277</p><p>While W.B., Faich G., Whelton A. et al, Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol,, 2002, 89, 425-430</p><p>Konstam M.A., Weir A.R. Current persective on the cardiovascular effects of coxibs. Clev. Clin. J. Med., 2002, (suppl), S1-47-SI-52.</p><p>Farcouh M.E., Kishner H., Harrington R.A. el al. on behalf of the TARGET Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthiritis Research and Gastrointestinal event trial (TARGET), cardiovascular outcome: randomized controlled I rial. Lancet ,2004, 364, 675-684</p><p>Baigcnt C., Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal Arthr. Rheum., 2003, 48, 12-20</p><p>Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and Ihe antiplatelet effect of aspirin. N. Engl. J. Med., 2001, 345, 1809-1817</p><p>Cippollone F., Rocca B., Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arteriol. Thromb. Vase. Biol., 2004, 24, 246-255</p><p>Linton M.F., Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol., 2004, 4, 116129</p><p>Chenevard R., Hurlimann D., Bcchir M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 2003, 107,405-409</p><p>Allman R., Luciardi H.L., Muntaner J. et al. Efficacy of assessment of meloxicam. A preferential COX-2 inhibitor in acute coronary syndromes without ST-segmenl elevation, the NUT-2 pilot study. Circulation, 2002, 106, 191-195</p><p>Stiller C.-О., Hjemdahl P. Endothelial COX-2 inhibition: possible relevance for hypertension and cardiovascular risk? J. Hypertension, 2003, 21, 1615-1618</p><p>Meune C., Mourad J.-J., Bergmann J.-B., Spaulding C. Interaction between cyclooxygenase and the rennin- angiotensin-aldosterone system: rationale and clinical relevance. JRAAS, 2003. 4, 149-154</p><p>Page J., Henry D.„Consumption of NSAIDs and the development of congestive heart failure in eldery patient: an unrecognized public health problem. Arch. Intern. Med., 2000, 160, 777-784</p><p>Modena M.G., Bonetti L., Coppi F. el al. Prognostic role of revereible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 2002, 40, 505510</p><p>Perticone F., Ceravolo R,, Pujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 2001, 104, 191-196</p><p>Wildansky M.E., Price D.T., Gokce N. et al. Short-and Long-Term COX-2 inhibition reserves endothelial dysfunction in patients with hypertension. Hypertension, 2003, 42, 310-315</p><p>Hermann М., Camici G., Fralton A. et al. Different effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation, 2003, 108, 2308-2311</p><p>Vaughan C.J., Golto A.M., Basson C.T. The evolving role of statins in the management of athrosclerosis, JACCI, 2000, 35, 1-10</p><p>Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ-КоА редуктазы. М., Реафарм, 2002, 112</p><p>Насонов Е.Л. Патогенетическое и клиническое обоснование применения статинов при системной красной волчанке и антифосфолипидном синдроме. Клин, фар- макол. тер., 2004, 13(1), 82-89</p><p>Насонов ЕЛ. Перспективы применения статинов в ревматологии, Р.М.Ж., 2003, 11, (23), 1273-1276</p><p>Meroni P.L., Raschi Е., Testoni С. et at. Statins prevent endothelial cell activation induced by antiphospholipid (anti- beta2-glycoprotein I) antibodies. Effect on the proadhesive and prounflammatory phenotype. Arthr. Rheum., 2001, 44,2870-2878</p><p>Ferrara D., Liu X., Espinola R.G. et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibody by fluvastatin in an in vitro model. Arthr. Rheum., 2003, 48, 3272-3279</p><p>Leung B.P., Sattar N., Crilly A. et al. A novel anti-inflammatory role for simvastatin in inflammatory atthritis. J. Immunol., 2003, 170, 1524-1530</p><p>Kanda H., Hamasaki K., Kubo K. et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J. Rheumatol., 2003,</p><p>McCarey D.W., Mclnnes 1.В., Madhok R. el al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet, 2004, 363, 2015-2021</p><p>Насонов Е.Л. Моноклональные антитела к фактору некроза опухоли в ревматологии. Р.М.Ж., 2003,11(7), 390-394</p><p>Ch'ta S., Quadan М., Newton R. et al. Intra-arterial tumor necrosis factor-alpha impairs endothelial-dependent dilatation in humans. Arterioscler. Thromb. Vase. Biol., 2003, 23, 695-701</p><p>Pasceri V., Willerson J.T., Yell E.T. Direct proinflammato- ry effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102, 2165-2168</p><p>Nacada M.T., Tam S.H., Woulfe D.S. et al. Neutralisation of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes. Commun., 1998, 491-503</p><p>Warrington K.J. Anti-tumor necrosis factor a therapy in rheumatoid arthritis: hitting two birds with one stone? Arthr. Care&amp;Res., 2004, 51, 309-310</p><p>Khanna D., McMahon М., Furst D.E. Anti-tumor necrosis factor a therapy and heart failure. Arthr. Rheum., 2004, 50, 1040-1050</p><p>Henriksen P.A., Newby D.E. Therapeutic inhibition of tumor necrosis factor a in patients with heart failure: cooling an inflamed heart. Heart, 2003, 89, 14-18</p><p>Kurth Т., Glynn R.J., Walker A.M. et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation, 2003, 108, 1191-1195</p></div><br />